FORTICAL Drug Patent Profile

When do Fortical patents expire, and when can generic versions of Fortical launch?

Fortical is a drug marketed by Upsher Smith Labs and is included in one NDA.

The generic ingredient in FORTICAL is calcitonin salmon recombinant. There are fourteen drug master file entries for this compound. Additional details are available on the calcitonin salmon recombinant profile page.

Summary for FORTICAL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	3,474
What excipients (inactive ingredients) are in FORTICAL?	FORTICAL excipients list
DailyMed Link:	FORTICAL at DailyMed

Recent Clinical Trials for FORTICAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	N/A
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	N/A

See all FORTICAL clinical trials

Paragraph IV (Patent) Challenges for FORTICAL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FORTICAL	Nasal Spray	calcitonin salmon recombinant	200 IU/spray	021406	1	2006-03-29

US Patents and Regulatory Information for FORTICAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005		DISCN	No	No

Expired US Patents for FORTICAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005

International Patents for FORTICAL

See the table below for patents covering FORTICAL around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	3660401
World Intellectual Property Organization (WIPO)	0156594
China	1422160

Market Dynamics and Financial Trajectory for Fortical

Last updated: January 15, 2026

Summary

Fortical (calcitonin-salmon) nasal spray, approved primarily for osteoporosis treatment and hypercalcemia management, has experienced varying market performances driven by evolving regulatory environments, competitive landscape, prescribing patterns, and technological advancements. This report analyzes the current market dynamics, financial trajectory, regulatory considerations, and competitive positioning of Fortical, providing essential insights for stakeholders evaluating its future prospects. Notably, the decline in sales post-2018 reflects shifting industry trends, yet emerging indications and new formulations could influence its trajectory.

---

What Is Fortical and Why Is Its Market Important?

Fortical is a recombinant salmon calcitonin nasal spray developed by Acadia Pharmaceuticals, primarily indicated for:

• Osteoporosis in postmenopausal women at heightened fracture risk (FDA approved in 2002, originally branded as Miacalcin).
• Hypercalcemia associated with malignancy

Despite its longstanding approval, Fortical’s market has steadily contracted, owing to safety concerns, the emergence of bisphosphonates, denosumab, and alternative therapeutic options.

---

Current Market Landscape and Key Drivers

1. Market Size and Revenue Trends

Year	Estimated Global Market Size (USD Billions)	Fortical Sales (USD Million)	Relative Market Share	Notes
2015	$4.0	$80	2%	Market peaked around 2014–2015
2018	$3.5	$20	~0.6%	Decline due to safety and competition
2022	$3.0	<$10	<0.3%	Further decline, limited growth prospects

Source: Industry reports (e.g., BCC Research, EvaluatePharma), company disclosures

2. Regulatory and Safety Concerns

• FDA Label Changes (2012): Issues regarding increased cancer risk with long-term calcitonin use led to a label update, limiting its use.
• European Medicines Agency (EMA): Suspended calcitonin’s use for osteoporosis due to safety concerns, further impacting sales.

3. Competitive Landscape

Competitors	Main Products	Market Position	Comments
Bisphosphonates	Alendronate, Risedronate, Ibandronate	Dominant first-line treatment	Proven efficacy, safety, lower cost
Denosumab	Prolia, Xgeva	Growing preference, injectable	Superior fracture risk reduction
Teriparatide & Abaloparatide	Forteo (ably, injectable)	Used for severe cases	Costly, injectable
Hormone-based therapies	Estradiol, SERMs	Limited due to safety concerns	Declining due to adverse effect profiles

Fortical holds a niche position, primarily in specific patient populations unable to tolerate first-line agents or requiring short-term therapy.

4. Prescribing Trends

• Shift toward oral therapies: Oral bisphosphonates dominate the osteoporosis landscape.
• Limited adoption of nasal calcitonin: Pervasively overshadowed by more efficacious or safer alternatives.
• Reimbursement hurdles: Cost-effectiveness challenges limit usage in some markets.

---

Financial Trajectory Analysis

1. Revenue and Profitability Trends

Year	Approximate Sales (USD Million)	Revenue Change	Comment
2014	~$80	--	Peak sales
2018	~$20	-75%	Sharp decline
2022	<$10	-50% (since 2018)	Continual decline

Note: Exact figures are proprietary; estimates derive from industry and financial analyst reports.

2. Factors Affecting Future Revenue

Factor	Impact on Revenue	Mitigation Strategies
Regulatory restrictions	Potential further restrictions or withdrawals	Advancing reformulation or repositioning
Competitive pressure	Attrition due to superior therapies	Differentiation via new indications or formulations
Patent and exclusivity status	No current patent protection; generic emergence possible	Explore new delivery systems or combination therapies
Market acceptance	Declining due to safety concerns	Focus on patient subsets with unmet needs

3. Cost Structure and R&D Outlook

• Manufacturing Costs: Relatively stable but influenced by scale.
• R&D Investment: Focused on new indications (e.g., early-stage osteoarthritis or desensitization therapies) and delivery innovations.
• Profit Margins: Marginal due to declining sales, emphasizing efficiency and niche markets.

---

What Are the Regulatory and Policy Considerations?

1. Regulatory Trends

• Global Differences: FDA remains cautious post-2012 safety label amendments; EMA has suspended calcitonin use.
• Off-label Use: Limited, but some clinicians explore for specific indications under clinical research or compassionate use.

2. Policy Shifts Favoring Safer Alternatives

• Push for safer osteoporosis therapies: Governments and insurers prioritize cost-effective, low-risk medications.
• Reimbursement policies: Favor newer biologicals and oral medications with proven safety profiles.

---

What Are the Future Opportunities and Challenges?

Opportunities

• Novel Indications: Investigating calcitonin’s role beyond osteoporosis, such as in osteoarthritis or pain management.
• Delivery Innovations: Developing more patient-friendly formulations or combination therapies.
• Biological Understanding: Enhanced understanding of calcitonin’s mechanisms could unlock new therapeutic pathways.

Challenges

• Preexisting Safety Perceptions: Long-term safety issues impede market acceptance.
• Intense Competition: Dominance of bisphosphonates and RANKL inhibitors like denosumab.
• Patent Expiry and Generics: Potential erosion of revenue streams if generic versions enter the market.

---

Comparison With Similar Drugs and Market Dynamics

Parameter	Fortical	Miacalcin (generic)	Denosumab (Prolia)	Zoledronic Acid (Reclast)
Approval Year	2002	2010 (generic)	2010	2007
Formulation	Nasal spray	Injectable	Injectable	IV infusion
Indications	Osteoporosis, hypercalcemia	Same	Same	Same
Market Position	Niche, declining	Similar	Leading oral/ injectable	Leading IV agent
Safety Profile	Concerns over cancer risk	Similar	Advantageous safety	Good safety profile

---

Key Takeaways

• Market decline is firmly established, with annual revenues now under $10 million globally due to safety concerns and preferred alternatives.
• Regulatory landscape heavily influences prospects, with bans and label restrictions reducing prescribing.
• Innovative repositioning and new indications could present avenues for growth, though significant hurdles remain.
• Competitive landscape favoring oral bisphosphonates and newer biologics diminishes Fortical’s niche appeal.
• Stakeholders should monitor ongoing research, regulatory developments, and potential delivery innovations that might revive its market trajectory.

---

FAQs

Q1: What are the main reasons for Fortical’s declining sales?
A1: Safety concerns linked to long-term cancer risks, regulatory restrictions, a shift towards more effective and safer oral therapies like bisphosphonates and denosumab, and limited new indications have led to declining sales.

Q2: Can Fortical regain market share through new formulations or indications?
A2: While theoretically possible, significant scientific evidence, regulatory approvals, and clinical trials are necessary. Its safety profile remains a hurdle, and competition is intense.

Q3: How does Fortical compare in safety to its competitors?
A3: Calcitonin has been associated with increased cancer risk in long-term use, whereas newer agents like denosumab and bisphosphonates generally have more favorable safety profiles, although they also carry their own risks.

Q4: Are there any markets where Fortical is still considered a first-line therapy?
A4: No, current guidelines favor bisphosphonates as first-line therapies; Fortical’s role is limited to niche or refractory cases.

Q5: What strategies could stakeholders pursue to improve Fortical’s market outlook?
A5: Exploration of new therapeutic indications, formulation innovations, combination therapies, and repositioning within specific patient populations or clinical settings.

---

References

1. EvaluatePharma. (2022). Pharmaceutical Market Data.
2. BCC Research. (2021). Osteoporosis and Bone Disease Market Trends.
3. U.S. Food and Drug Administration. (2012). Label Update for Calcitonin-containing Products.
4. European Medicines Agency. (2013). Assessment Report on Calcitonin-containing Products.
5. American Society for Bone and Mineral Research. (2020). Osteoporosis Treatment Guidelines.